ArticleJournal of neurology, neurosurgery, and psychiatry2005
A comparison of health utility measures for the evaluation of multiple sclerosis treatments.
Article in Journal of neurology, neurosurgery, and psychiatry, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 81 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
81 citing papers in PubMed, 5 syntheses or guidelines pooled it.
- The correlation between 9-HPT and patient-reported measures of upper limb function in multiple sclerosis: a systematic review and meta-analysis.Journal of neurology · 2023Pooled it
- Comparative evaluation of the health utilities index mark 3 and the short form 6D: evidence from an individual participant data meta-analysis of very preterm and very low birthweight adults.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2023Pooled it
- Pooled it
- Pooled it
- Pooled it
- Early exercise after spinal cord injury ('Switch-On'): study protocol for a randomised controlled trial.Trials · 2015Trial
- Use of the Tailored Activities Program to reduce neuropsychiatric behaviors in dementia: an Australian protocol for a randomized trial to evaluate its effectiveness.International psychogeriatrics · 2014Trial
- Quality of life, disability, well-being, and coping strategies in patients undergoing neurosurgical procedures: preoperative results in an Italian sample.TheScientificWorldJournal · 2014Trial
- A pragmatic parallel arm multi-centre randomised controlled trial to assess the effectiveness and cost-effectiveness of a group-based fatigue management programme (FACETS) for people with multiple sclerosis.Journal of neurology, neurosurgery, and psychiatry · 2013Trial
- Impact of mobility impairment on indirect costs and health-related quality of life in multiple sclerosis.PloS one · 2013Trial
- Measuring health-related quality of life in multiple sclerosis: comparing the acceptability, validity and responsiveness of the EQ-5D-3L and MSIS-8D.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2026Article
- Health utility adjusted survival: A composite endpoint for clinical trial designs.Statistical methods in medical research · 2025Article
- Development and Preliminary Validation of a Parkinsonism-Dystonia Scale for Infants and Young Children.Movement disorders : official journal of the Movement Disorder Society · 2025Article
- Health Utility Survival for Randomized Clinical Trials: Extensions and Statistical Properties.Statistics in medicine · 2025Article
- Access to Care and Health-Related Quality of Life in Multiple Sclerosis.Neurology. Clinical practice · 2024Article
- Exploring the Major Barriers to Physical Activity in Persons With Multiple Sclerosis: Observational Longitudinal Study.JMIR rehabilitation and assistive technologies · 2024Article
- Assessment of health-related quality of life in individuals with depressive symptoms: validity and responsiveness of the EQ-5D-3L and the SF-6D.The European journal of health economics : HEPAC : health economics in prevention and care · 2023Article
- Assessing quality of life with SarQol is useful in screening for sarcopenia and sarcopenic obesity in older women.Aging clinical and experimental research · 2023Article
- Psychosocial factors associated with workability after surgery in cancer survivors: An explorative study.Journal of health psychology · 2023Article
- The Gut Dysmotility Questionnaire for Parkinson's disease: Insights into development and pretest studies.Frontiers in neurology · 2023Article
21 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo evaluate the practical application and psychometric properties of three health utility measures in a sample of MS patients with a broad range of neurological disability as measured by the Extended Disability Status Scale (EDSS).
methodsPatients randomly selected from two MS clinic registries were assessed using standard clinical methods and completed three generic measures of health utility (EQ-5D, HUI Mark III, SF-6D). The proportion of missing data, test/retest reliability, and construct validity of each health utility measure were examined.
resultsThe assessments were completed by 187 patients. Less than 10% of data were missing for the subscales of the SF-6D (< 3.2%), HUI Mark III (<1.6%), and EQ-5D (< or =7.5%). Severely disabled patients were more likely to omit physical function questions for the SF-6D (20%), and EQ-5D (43%). Retest reliability for the SF-6D (ICC = 0.83), EQ-5D (ICC = 0.81), and HUI Mark III (ICC = 0.87) were adequate for population surveys. Correlations between assessment of clinical function and each health utility measure were strongest for the HUI Mark III (HUI Mark III EDSS rho = -0.77, HUI Mark III ambulation index rho = -0.76, HUI Mark III timed 25 foot walk rho = -0.73, HUI Mark III nine hole peg test rho = -0.65).
conclusionsThe health utility measures were generally feasible and reliable but the HUI Mark III demonstrated highest concordance with the EDSS across the full range of neurological disability. Of the three measures studied, the HUI Mark III may be the most appropriate for cost effectiveness evaluations of MS therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.